Cybin to participate at the 27th annual milken institute global conference

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that doug drysdale, cybin's chief executive officer, will be speaking at the 27th annual milken institute global conference on a panel entitled “collaborating for improved mental health.” the conference wil.
CYBN Ratings Summary
CYBN Quant Ranking